Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PS5P | ISIN: US35104E1001 | Ticker-Symbol:
NASDAQ
06.06.25 | 22:00
4,350 US-Dollar
+11,25 % +0,440
1-Jahres-Chart
4D MOLECULAR THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
4D MOLECULAR THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur 4D MOLECULAR THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
16.05.4D Molecular Therapeutics, Inc.: 4DMT Announces New Employment Inducement Grants159EMERYVILLE, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...
► Artikel lesen
09.05.4D Molecular Therapeutics GAAP EPS of -$0.86 misses by $0.02, revenue of $0.01M misses by $0.44M5
08.05.4D Molecular Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
08.05.4D Molecular Therapeutics, Inc. - 10-Q, Quarterly Report1
08.05.4D Molecular Therapeutics, Inc. - 8-K, Current Report-
08.05.4D Molecular Therapeutics, Inc.: 4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones136Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to dateInitiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) expected...
► Artikel lesen
01.05.4D Molecular Therapeutics' 4D-150 Receives RMAT Designation For Diabetic Macular Edema1
4D MOLECULAR THERAPEUTICS Aktie jetzt für 0€ handeln
01.05.4D Molecular Therapeutics gets FDA RMAT status for macular edema treatment3
01.05.4D Molecular Therapeutics, Inc.: 4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME119EMERYVILLE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...
► Artikel lesen
11.04.4D Molecular Therapeutics, Inc.: 4DMT Announces New Employment Inducement Grants174EMERYVILLE, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...
► Artikel lesen
10.03.4D Molecular Therapeutics, Inc.: 4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD346EMERYVILLE, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...
► Artikel lesen
03.03.Forecasting The Future: 7 Analyst Projections For 4D Molecular Therapeutics12
28.02.4D Molecular Therapeutics, Inc.: 4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones1.138Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populations...
► Artikel lesen
28.02.4D Molecular Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
28.02.4D Molecular Therapeutics, Inc. - 8-K, Current Report-
10.02.Jefferies cuts 4D Molecular Therapeutics target to $406
10.02.Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study4
10.02.H.C. Wainwright maintains buy on 4D Molecular Therapeutics stock4
10.02.4D Molecular Therapeutics, Inc. - 8-K, Current Report3
10.02.A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 9 Analysts2
Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1